# pathway_0197: before and after transfer clarification

[All 1,328 cases](../README.md) · [Method](../METHOD.md) · [Summary](../SUMMARY.md) · [Exact reviewer user message](../inputs/pathway_0197.txt)

**Task:** `pathway`  
**Author key, unchanged:** **C** — Antifungal biosynthesis. .

| Round | Reviewer | Key support | Transfer / lookup | Output usability (canonical status) |
|---|---|---|---|---|
| before | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| before | Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent | usable output (valid_review) |
| after | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| after | Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent | usable output (valid_review) |

**Usable output means format-valid review, not reasoning-supported or biologically correct.** A usable output can classify the question as reasoning-supported, lookup-dependent or uncertain. An output error is a problem with the saved model response; it does not count a defective benchmark question or wrong key. Each saved review is retained in full below. Labels from output errors are displayed as saved and excluded from label statistics. The author key and reviewer evidence were visible to reviewers; this is a review of answerability and key support, not a benchmark-solving score.

## Complete original question

```text
[Protein Sequence]
MKAIISVSPGRAALVHDRPLPSLRNGYLLVRTKAVALNPTDWKHIEITERPGILFGCDYAGVVEKIGPGISSRFQVGDRVAGFVHGGNSQEPQDGAFAEYILAKADIQILIPEHMSFEEAATLGVGVTSVGQGLYQALQLPFPGTQGEDPKTPTEEQQPLLIYGGSTASGVLGIQFAKLSGFAPLAVCSPDHFDLVETLGAVAQFDYADGEEAVQEIQDYVDRMSKPLRLAWDTVSIPSSAQFCGDALSALDECHYASLLPIKCQRSDVTSTTTMAYTVFGEDWGMGATRFPAVATDAEFGRRWWALVQELLDQGRIQTHRIIIGENGLDGVLAGLERLRDSQVRGAKLVYRV

[Multiple Choices]
A. O-acetyl-L-homoserine from L-homoserine: step 1/1. .
B. Protein biosynthesis
C. Antifungal biosynthesis. .
D. Secondary metabolite biosynthesis. .
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Four saved visible reviews

## Before: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches the UniProt entry for trans-enoyl reductase rstn7, whose pathway annotation is “Antifungal biosynthesis” and cites a 2021 publication. The historical entry also contains this annotation, so the key is supported, though the primary paper was not independently reviewed here.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence is consistent with an enzyme, which may make protein biosynthesis less plausible, but it does not by itself establish which specific biosynthetic pathway the enzyme serves.


**Missing item-specific fact**

> The protein-specific association of Rstn7 with the restricticin biosynthetic cluster and its antifungal-biosynthesis role.


**Reason**

> Distinguishing antifungal biosynthesis from other secondary-metabolite pathways requires a protein-specific annotation or equivalent knowledge not supplied in the question. Recognizing or looking up this sequence could provide that fact, but would not constitute reasoning from the supplied input.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "C",
  "D"
]
```

> Antifungal biosynthesis is a specific kind of secondary-metabolite biosynthesis, so option D is a broader description that also applies. Option C is the more specific pathway annotation, but the choices are not mutually exclusive.


### Important caveats

- The reviewer-only annotation is sequence-matched, but the author’s exact source snapshot is unknown.
- The cited pathway annotation is evidence for the key; the cited primary paper was not independently assessed here.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is consistent with an enzyme, which may make protein biosynthesis less plausible, but it does not by itself establish which specific biosynthetic pathway the enzyme serves.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein-specific association of Rstn7 with the restricticin biosynthetic cluster and its antifungal-biosynthesis role.",
    "reason": "Distinguishing antifungal biosynthesis from other secondary-metabolite pathways requires a protein-specific annotation or equivalent knowledge not supplied in the question. Recognizing or looking up this sequence could provide that fact, but would not constitute reasoning from the supplied input."
  },
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for trans-enoyl reductase rstn7, whose pathway annotation is “Antifungal biosynthesis” and cites a 2021 publication. The historical entry also contains this annotation, so the key is supported, though the primary paper was not independently reviewed here."
  },
  "important_caveats": [
    "The reviewer-only annotation is sequence-matched, but the author’s exact source snapshot is unknown.",
    "The cited pathway annotation is evidence for the key; the cited primary paper was not independently assessed here."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "C",
      "D"
    ],
    "reason": "Antifungal biosynthesis is a specific kind of secondary-metabolite biosynthesis, so option D is a broader description that also applies. Option C is the more specific pathway annotation, but the choices are not mutually exclusive."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for trans-enoyl reductase rstn7, whose pathway annotation is “Antifungal biosynthesis” and cites a 2021 publication. The historical entry also contains this annotation, so the key is supported, though the primary paper was not independently reviewed here.",
    "evidence_ids": ["C4", "C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence is consistent with an enzyme, which may make protein biosynthesis less plausible, but it does not by itself establish which specific biosynthetic pathway the enzyme serves.",
    "missing_item_specific_fact": "The protein-specific association of Rstn7 with the restricticin biosynthetic cluster and its antifungal-biosynthesis role.",
    "reason": "Distinguishing antifungal biosynthesis from other secondary-metabolite pathways requires a protein-specific annotation or equivalent knowledge not supplied in the question. Recognizing or looking up this sequence could provide that fact, but would not constitute reasoning from the supplied input."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["C", "D"],
    "reason": "Antifungal biosynthesis is a specific kind of secondary-metabolite biosynthesis, so option D is a broader description that also applies. Option C is the more specific pathway annotation, but the choices are not mutually exclusive."
  },
  "important_caveats": [
    "The reviewer-only annotation is sequence-matched, but the author’s exact source snapshot is unknown.",
    "The cited pathway annotation is evidence for the key; the cited primary paper was not independently assessed here."
  ]
}
```

</details>

## Before: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry A0A0L1JEX1 (sequence matched exactly, 353 AA) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (direct assay) from PubMed:33857369. The protein is identified as Trans-enoyl reductase rstn7, part of the restricticin biosynthesis cluster. Restricticin is a CYP51 inhibitor with antifungal activity, as demonstrated in the cited JACS 2021 paper. The historical entry (version 28) contains the same pathway annotation.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence contains motifs consistent with a trans-enoyl reductase domain (e.g., 'GQGLY' and related enoyl reductase signatures), identifying it as a component of a modular polyketide/nonribosomal peptide synthetase assembly line. This general feature points toward secondary metabolite biosynthesis (D). However, the specific 'Antifungal biosynthesis' (C) designation depends on knowing that the end product of this cluster (restricticin) inhibits CYP51 and is classified as an antifungal agent — a property of the final compound, not of the enzyme domain itself.


**Missing item-specific fact**

> Knowledge that the rstn7-containing biosynthetic gene cluster produces restricticin, a CYP51 inhibitor classified under the 'Antifungal biosynthesis' pathway in UniProt, rather than the broader 'Secondary metabolite biosynthesis' category. This product-level biological activity annotation is not inferable from the enoyl reductase domain sequence alone.


**Reason**

> From the sequence, a model can reasonably identify a trans-enoyl reductase domain within a fungal secondary metabolite biosynthetic assembly line, supporting option D. Distinguishing C from D requires knowing that this specific cluster's product (restricticin) is an antifungal CYP51 inhibitor and that UniProt classifies it under 'Antifungal biosynthesis' rather than the generic 'Secondary metabolite biosynthesis' label. This is an item-specific database annotation fact.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "C",
  "D"
]
```

> Restricticin is simultaneously a secondary metabolite and an antifungal agent. Option D ('Secondary metabolite biosynthesis') is a valid broader description of the pathway this enzyme participates in. Option C ('Antifungal biosynthesis') is the specific UniProt pathway annotation. Without the database-specific classification, the sequence features of an enoyl reductase domain in a fungal PKS/NRPS cluster do not uniquely favor C over D. The question relies on the specific UniProt pathway label to disambiguate.


### Important caveats

- The evidence code ECO:0000269 (direct assay) confirms experimental support for the antifungal annotation, but this experimental knowledge is not derivable from the sequence.
- The UniProt pathway taxonomy places this under 'Antifungal biosynthesis' rather than a generic 'Secondary metabolite biosynthesis' heading, which is a database-specific classification choice.
- Options A and B are clearly incorrect distractors (homoserine O-acetyltransferase reaction; ribosomal protein synthesis), so the effective discrimination is between C and D.
- The accession and pathway annotation were absent from the evaluated model input; the model sees only the 353-aa sequence and four choices.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains motifs consistent with a trans-enoyl reductase domain (e.g., 'GQGLY' and related enoyl reductase signatures), identifying it as a component of a modular polyketide/nonribosomal peptide synthetase assembly line. This general feature points toward secondary metabolite biosynthesis (D). However, the specific 'Antifungal biosynthesis' (C) designation depends on knowing that the end product of this cluster (restricticin) inhibits CYP51 and is classified as an antifungal agent — a property of the final compound, not of the enzyme domain itself.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "Knowledge that the rstn7-containing biosynthetic gene cluster produces restricticin, a CYP51 inhibitor classified under the 'Antifungal biosynthesis' pathway in UniProt, rather than the broader 'Secondary metabolite biosynthesis' category. This product-level biological activity annotation is not inferable from the enoyl reductase domain sequence alone.",
    "reason": "From the sequence, a model can reasonably identify a trans-enoyl reductase domain within a fungal secondary metabolite biosynthetic assembly line, supporting option D. Distinguishing C from D requires knowing that this specific cluster's product (restricticin) is an antifungal CYP51 inhibitor and that UniProt classifies it under 'Antifungal biosynthesis' rather than the generic 'Secondary metabolite biosynthesis' label. This is an item-specific database annotation fact."
  },
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEX1 (sequence matched exactly, 353 AA) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (direct assay) from PubMed:33857369. The protein is identified as Trans-enoyl reductase rstn7, part of the restricticin biosynthesis cluster. Restricticin is a CYP51 inhibitor with antifungal activity, as demonstrated in the cited JACS 2021 paper. The historical entry (version 28) contains the same pathway annotation."
  },
  "important_caveats": [
    "The evidence code ECO:0000269 (direct assay) confirms experimental support for the antifungal annotation, but this experimental knowledge is not derivable from the sequence.",
    "The UniProt pathway taxonomy places this under 'Antifungal biosynthesis' rather than a generic 'Secondary metabolite biosynthesis' heading, which is a database-specific classification choice.",
    "Options A and B are clearly incorrect distractors (homoserine O-acetyltransferase reaction; ribosomal protein synthesis), so the effective discrimination is between C and D.",
    "The accession and pathway annotation were absent from the evaluated model input; the model sees only the 353-aa sequence and four choices."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "C",
      "D"
    ],
    "reason": "Restricticin is simultaneously a secondary metabolite and an antifungal agent. Option D ('Secondary metabolite biosynthesis') is a valid broader description of the pathway this enzyme participates in. Option C ('Antifungal biosynthesis') is the specific UniProt pathway annotation. Without the database-specific classification, the sequence features of an enoyl reductase domain in a fungal PKS/NRPS cluster do not uniquely favor C over D. The question relies on the specific UniProt pathway label to disambiguate."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEX1 (sequence matched exactly, 353 AA) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (direct assay) from PubMed:33857369. The protein is identified as Trans-enoyl reductase rstn7, part of the restricticin biosynthesis cluster. Restricticin is a CYP51 inhibitor with antifungal activity, as demonstrated in the cited JACS 2021 paper. The historical entry (version 28) contains the same pathway annotation.",
    "evidence_ids": ["C1", "C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence contains motifs consistent with a trans-enoyl reductase domain (e.g., 'GQGLY' and related enoyl reductase signatures), identifying it as a component of a modular polyketide/nonribosomal peptide synthetase assembly line. This general feature points toward secondary metabolite biosynthesis (D). However, the specific 'Antifungal biosynthesis' (C) designation depends on knowing that the end product of this cluster (restricticin) inhibits CYP51 and is classified as an antifungal agent — a property of the final compound, not of the enzyme domain itself.",
    "missing_item_specific_fact": "Knowledge that the rstn7-containing biosynthetic gene cluster produces restricticin, a CYP51 inhibitor classified under the 'Antifungal biosynthesis' pathway in UniProt, rather than the broader 'Secondary metabolite biosynthesis' category. This product-level biological activity annotation is not inferable from the enoyl reductase domain sequence alone.",
    "reason": "From the sequence, a model can reasonably identify a trans-enoyl reductase domain within a fungal secondary metabolite biosynthetic assembly line, supporting option D. Distinguishing C from D requires knowing that this specific cluster's product (restricticin) is an antifungal CYP51 inhibitor and that UniProt classifies it under 'Antifungal biosynthesis' rather than the generic 'Secondary metabolite biosynthesis' label. This is an item-specific database annotation fact."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["C", "D"],
    "reason": "Restricticin is simultaneously a secondary metabolite and an antifungal agent. Option D ('Secondary metabolite biosynthesis') is a valid broader description of the pathway this enzyme participates in. Option C ('Antifungal biosynthesis') is the specific UniProt pathway annotation. Without the database-specific classification, the sequence features of an enoyl reductase domain in a fungal PKS/NRPS cluster do not uniquely favor C over D. The question relies on the specific UniProt pathway label to disambiguate."
  },
  "important_caveats": [
    "The evidence code ECO:0000269 (direct assay) confirms experimental support for the antifungal annotation, but this experimental knowledge is not derivable from the sequence.",
    "The UniProt pathway taxonomy places this under 'Antifungal biosynthesis' rather than a generic 'Secondary metabolite biosynthesis' heading, which is a database-specific classification choice.",
    "Options A and B are clearly incorrect distractors (homoserine O-acetyltransferase reaction; ribosomal protein synthesis), so the effective discrimination is between C and D.",
    "The accession and pathway annotation were absent from the evaluated model input; the model sees only the 353-aa sequence and four choices."
  ]
}
```

</details>

## After: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The sequence-matched UniProt annotation assigns the protein to antifungal biosynthesis and cites experimental evidence (ECO:0000269) and a publication. This supports the key, though the underlying study was not independently evaluated here.

Citations as saved: [C5](#evidence-c5), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence is compatible with an enzyme involved in specialized-metabolite biosynthesis, which makes the broad secondary-metabolite option plausible. But an enzyme's general catalytic role does not establish that its product is antifungal rather than another specialized metabolite.


**Missing item-specific fact**

> The protein's assignment to the biosynthetic cluster for an antifungal product, or equivalent target-specific pathway evidence.


**Reason**

> The offered choices include both a broad secondary-metabolite category and the narrower antifungal-biosynthesis category. The sequence alone does not provide a credible basis to make that product-specific distinction; it requires information about this protein's pathway or cluster.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "C",
  "D"
]
```

> Antifungal biosynthesis is a form of secondary-metabolite biosynthesis, so both choices can describe the protein at different levels of specificity. The question does not specify that the most specific applicable pathway must be selected.


### Important caveats

- The supporting pathway annotation cites experimental evidence, but the primary study was not independently checked.
- Reviewer-only source identity and annotations were not part of the original model input and do not establish sequence-only answerability.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence is compatible with an enzyme involved in specialized-metabolite biosynthesis, which makes the broad secondary-metabolite option plausible. But an enzyme's general catalytic role does not establish that its product is antifungal rather than another specialized metabolite.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein's assignment to the biosynthetic cluster for an antifungal product, or equivalent target-specific pathway evidence.",
    "reason": "The offered choices include both a broad secondary-metabolite category and the narrower antifungal-biosynthesis category. The sequence alone does not provide a credible basis to make that product-specific distinction; it requires information about this protein's pathway or cluster."
  },
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "evidence_ids": [
      "C5",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The sequence-matched UniProt annotation assigns the protein to antifungal biosynthesis and cites experimental evidence (ECO:0000269) and a publication. This supports the key, though the underlying study was not independently evaluated here."
  },
  "important_caveats": [
    "The supporting pathway annotation cites experimental evidence, but the primary study was not independently checked.",
    "Reviewer-only source identity and annotations were not part of the original model input and do not establish sequence-only answerability."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "C",
      "D"
    ],
    "reason": "Antifungal biosynthesis is a form of secondary-metabolite biosynthesis, so both choices can describe the protein at different levels of specificity. The question does not specify that the most specific applicable pathway must be selected."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The sequence-matched UniProt annotation assigns the protein to antifungal biosynthesis and cites experimental evidence (ECO:0000269) and a publication. This supports the key, though the underlying study was not independently evaluated here.",
    "evidence_ids": ["C5", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence is compatible with an enzyme involved in specialized-metabolite biosynthesis, which makes the broad secondary-metabolite option plausible. But an enzyme's general catalytic role does not establish that its product is antifungal rather than another specialized metabolite.",
    "missing_item_specific_fact": "The protein's assignment to the biosynthetic cluster for an antifungal product, or equivalent target-specific pathway evidence.",
    "reason": "The offered choices include both a broad secondary-metabolite category and the narrower antifungal-biosynthesis category. The sequence alone does not provide a credible basis to make that product-specific distinction; it requires information about this protein's pathway or cluster."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["C", "D"],
    "reason": "Antifungal biosynthesis is a form of secondary-metabolite biosynthesis, so both choices can describe the protein at different levels of specificity. The question does not specify that the most specific applicable pathway must be selected."
  },
  "important_caveats": [
    "The supporting pathway annotation cites experimental evidence, but the primary study was not independently checked.",
    "Reviewer-only source identity and annotations were not part of the original model input and do not establish sequence-only answerability."
  ]
}
```

</details>

## After: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry A0A0L1JEX1 (RSTN7_ASPN3) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (experimental) from PubMed:33857369. The protein is 'Trans-enoyl reductase rstn7,' a component of the restricticin biosynthetic gene cluster. Restricticin is a natural product CYP51 inhibitor, and CYP51 inhibition confers antifungal activity. The annotation is directly supported by experimental characterization in the cited JACS 2021 paper.

Citations as saved: [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence contains multiple glycine-rich Rossmann-fold-like motifs (GCDYAGVVEKIGPG, GGSTASGVLGIQFAKLSGF, ENGLDGVLAGLERLR) characteristic of an oxidoreductase, likely a trans-enoyl reductase component of a fungal polyketide synthase. This eliminates A (homoserine O-acetyltransferase, a transferase) and B (ribosomal/translation machinery). However, distinguishing C ('Antifungal biosynthesis') from D ('Secondary metabolite biosynthesis') requires knowing that this specific trans-enoyl reductase belongs to the restricticin cluster AND that restricticin's biological activity is antifungal (CYP51 inhibition). Trans-enoyl reductases are generic PKS components found in many fungal secondary metabolite pathways (aflatoxin, lovastatin, gliotoxin, etc.), and their sequences do not encode information about the biological activity of the final polyketide product. No sequence feature or family-level inference distinguishes an antifungal-targeting PKS from one producing an antibacterial or other bioactive secondary metabolite.


**Missing item-specific fact**

> The specific identity of the biosynthetic gene cluster (restricticin) and the experimentally determined antifungal (CYP51-inhibitory) activity of the end product, which together justify the specific 'Antifungal biosynthesis' pathway annotation over the general 'Secondary metabolite biosynthesis' category.


**Reason**

> From the sequence alone, a model can identify an oxidoreductase likely involved in fungal secondary metabolism (polyketide biosynthesis), but cannot determine whether the end product is specifically antifungal versus any other class of secondary metabolite. The C vs D distinction depends on knowing the biological activity of restricticin, which is a fact specific to this protein's role in this particular biosynthetic cluster.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "C",
  "D"
]
```

> Restricticin is both a secondary metabolite and an antifungal compound. 'Secondary metabolite biosynthesis' (D) is the general biochemical category, while 'Antifungal biosynthesis' (C) is the specific functional annotation in UniProt. Without the taxonomy hierarchy being explicit in the question, a model could argue D is the broader correct category encompassing C, or that C is the more specific pathway annotation. The distinction requires knowing the benchmark's pathway taxonomy treats these as mutually exclusive categories with C being the specific assigned pathway.


### Important caveats

- The UniProt 'Antifungal biosynthesis' pathway annotation (ECO:0000269) is based on experimental characterization of the restricticin cluster's CYP51-inhibitory activity, not on sequence analysis of this individual enzyme.
- The sequence identifies the protein as a trans-enoyl reductase (oxidoreductase), which is consistent with both C and D but does not uniquely specify either.
- The reviewer-only evidence confirms sequence match to A0A0L1JEX1 (353 aa, SHA256 match), but this accession and organism identity were not available to the evaluated model.
- The historical entry (version 28, released 2026-01-28) already contained the 'Antifungal biosynthesis' pathway annotation, so the key was available in the database at the approximate benchmark construction time.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence contains multiple glycine-rich Rossmann-fold-like motifs (GCDYAGVVEKIGPG, GGSTASGVLGIQFAKLSGF, ENGLDGVLAGLERLR) characteristic of an oxidoreductase, likely a trans-enoyl reductase component of a fungal polyketide synthase. This eliminates A (homoserine O-acetyltransferase, a transferase) and B (ribosomal/translation machinery). However, distinguishing C ('Antifungal biosynthesis') from D ('Secondary metabolite biosynthesis') requires knowing that this specific trans-enoyl reductase belongs to the restricticin cluster AND that restricticin's biological activity is antifungal (CYP51 inhibition). Trans-enoyl reductases are generic PKS components found in many fungal secondary metabolite pathways (aflatoxin, lovastatin, gliotoxin, etc.), and their sequences do not encode information about the biological activity of the final polyketide product. No sequence feature or family-level inference distinguishes an antifungal-targeting PKS from one producing an antibacterial or other bioactive secondary metabolite.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The specific identity of the biosynthetic gene cluster (restricticin) and the experimentally determined antifungal (CYP51-inhibitory) activity of the end product, which together justify the specific 'Antifungal biosynthesis' pathway annotation over the general 'Secondary metabolite biosynthesis' category.",
    "reason": "From the sequence alone, a model can identify an oxidoreductase likely involved in fungal secondary metabolism (polyketide biosynthesis), but cannot determine whether the end product is specifically antifungal versus any other class of secondary metabolite. The C vs D distinction depends on knowing the biological activity of restricticin, which is a fact specific to this protein's role in this particular biosynthetic cluster."
  },
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "evidence_ids": [
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEX1 (RSTN7_ASPN3) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (experimental) from PubMed:33857369. The protein is 'Trans-enoyl reductase rstn7,' a component of the restricticin biosynthetic gene cluster. Restricticin is a natural product CYP51 inhibitor, and CYP51 inhibition confers antifungal activity. The annotation is directly supported by experimental characterization in the cited JACS 2021 paper."
  },
  "important_caveats": [
    "The UniProt 'Antifungal biosynthesis' pathway annotation (ECO:0000269) is based on experimental characterization of the restricticin cluster's CYP51-inhibitory activity, not on sequence analysis of this individual enzyme.",
    "The sequence identifies the protein as a trans-enoyl reductase (oxidoreductase), which is consistent with both C and D but does not uniquely specify either.",
    "The reviewer-only evidence confirms sequence match to A0A0L1JEX1 (353 aa, SHA256 match), but this accession and organism identity were not available to the evaluated model.",
    "The historical entry (version 28, released 2026-01-28) already contained the 'Antifungal biosynthesis' pathway annotation, so the key was available in the database at the approximate benchmark construction time."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "C",
      "D"
    ],
    "reason": "Restricticin is both a secondary metabolite and an antifungal compound. 'Secondary metabolite biosynthesis' (D) is the general biochemical category, while 'Antifungal biosynthesis' (C) is the specific functional annotation in UniProt. Without the taxonomy hierarchy being explicit in the question, a model could argue D is the broader correct category encompassing C, or that C is the more specific pathway annotation. The distinction requires knowing the benchmark's pathway taxonomy treats these as mutually exclusive categories with C being the specific assigned pathway."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0197",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEX1 (RSTN7_ASPN3) explicitly annotates the pathway as 'Antifungal biosynthesis' with evidence code ECO:0000269 (experimental) from PubMed:33857369. The protein is 'Trans-enoyl reductase rstn7,' a component of the restricticin biosynthetic gene cluster. Restricticin is a natural product CYP51 inhibitor, and CYP51 inhibition confers antifungal activity. The annotation is directly supported by experimental characterization in the cited JACS 2021 paper.",
    "evidence_ids": ["C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence contains multiple glycine-rich Rossmann-fold-like motifs (GCDYAGVVEKIGPG, GGSTASGVLGIQFAKLSGF, ENGLDGVLAGLERLR) characteristic of an oxidoreductase, likely a trans-enoyl reductase component of a fungal polyketide synthase. This eliminates A (homoserine O-acetyltransferase, a transferase) and B (ribosomal/translation machinery). However, distinguishing C ('Antifungal biosynthesis') from D ('Secondary metabolite biosynthesis') requires knowing that this specific trans-enoyl reductase belongs to the restricticin cluster AND that restricticin's biological activity is antifungal (CYP51 inhibition). Trans-enoyl reductases are generic PKS components found in many fungal secondary metabolite pathways (aflatoxin, lovastatin, gliotoxin, etc.), and their sequences do not encode information about the biological activity of the final polyketide product. No sequence feature or family-level inference distinguishes an antifungal-targeting PKS from one producing an antibacterial or other bioactive secondary metabolite.",
    "missing_item_specific_fact": "The specific identity of the biosynthetic gene cluster (restricticin) and the experimentally determined antifungal (CYP51-inhibitory) activity of the end product, which together justify the specific 'Antifungal biosynthesis' pathway annotation over the general 'Secondary metabolite biosynthesis' category.",
    "reason": "From the sequence alone, a model can identify an oxidoreductase likely involved in fungal secondary metabolism (polyketide biosynthesis), but cannot determine whether the end product is specifically antifungal versus any other class of secondary metabolite. The C vs D distinction depends on knowing the biological activity of restricticin, which is a fact specific to this protein's role in this particular biosynthetic cluster."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["C", "D"],
    "reason": "Restricticin is both a secondary metabolite and an antifungal compound. 'Secondary metabolite biosynthesis' (D) is the general biochemical category, while 'Antifungal biosynthesis' (C) is the specific functional annotation in UniProt. Without the taxonomy hierarchy being explicit in the question, a model could argue D is the broader correct category encompassing C, or that C is the more specific pathway annotation. The distinction requires knowing the benchmark's pathway taxonomy treats these as mutually exclusive categories with C being the specific assigned pathway."
  },
  "important_caveats": [
    "The UniProt 'Antifungal biosynthesis' pathway annotation (ECO:0000269) is based on experimental characterization of the restricticin cluster's CYP51-inhibitory activity, not on sequence analysis of this individual enzyme.",
    "The sequence identifies the protein as a trans-enoyl reductase (oxidoreductase), which is consistent with both C and D but does not uniquely specify either.",
    "The reviewer-only evidence confirms sequence match to A0A0L1JEX1 (353 aa, SHA256 match), but this accession and organism identity were not available to the evaluated model.",
    "The historical entry (version 28, released 2026-01-28) already contained the 'Antifungal biosynthesis' pathway annotation, so the key was available in the database at the approximate benchmark construction time."
  ]
}
```

</details>

## Existing project source checks of the old Luna review only

These unchanged notes concern the earlier Luna claims. They do not validate either new review or the old Qwen review. No new scientific adjudication was performed.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Complete reviewer-only evidence and qualifications

All excerpts supplied in the original and revised reviewer user message follow. This material was not available to the original evaluated model. Accession identity came from dataset image-path metadata. Source support and transferable discrimination are separate judgments.

**Applicability metadata, unchanged:**

```json
{
  "requested_accession": "A0A0L1JEX1",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "benchmark_sequence_sha256": "39f6a97cab7f2cacfcd71868b53ec0e747754ce4dcb5969ed28596b1d58ba3ca",
  "benchmark_sequence_length": 353,
  "current_status": "retrieved",
  "current_sequence_comparison": "matched",
  "current_entry_audit": {
    "entryVersion": 30,
    "firstPublicDate": "2025-02-05",
    "lastAnnotationUpdateDate": "2026-09-02",
    "lastSequenceUpdateDate": "2015-11-11",
    "sequenceVersion": 1
  },
  "current_uniprot_release": "2026_03",
  "current_record_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "current_source_sequence_sha256": "39f6a97cab7f2cacfcd71868b53ec0e747754ce4dcb5969ed28596b1d58ba3ca",
  "current_source_sequence_length": 353,
  "historical_status": "retrieved",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "selected_historical_entry_version": 28,
  "selected_historical_version": {
    "accession": "A0A0L1JEX1",
    "database": "Swiss-Prot",
    "entryVersion": 28,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_01/2026_01",
    "lastReleaseDate": "28-Jan-2026",
    "name": "RSTN7_ASPN3",
    "sequenceVersion": 1
  },
  "selected_historical_record_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "selected_historical_source_sequence_sha256": "39f6a97cab7f2cacfcd71868b53ec0e747754ce4dcb5969ed28596b1d58ba3ca",
  "selected_historical_source_sequence_length": 353,
  "latest_at_cutoff_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 28,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "actual_author_source_snapshot": "unknown",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed."
}
```

**Qualifications, unchanged:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C1",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "json_pointer": "/primaryAccession",
  "excerpt": "\"A0A0L1JEX1\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C2",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "json_pointer": "/entryAudit",
  "excerpt": "{\"entryVersion\":30,\"firstPublicDate\":\"2025-02-05\",\"lastAnnotationUpdateDate\":\"2026-09-02\",\"lastSequenceUpdateDate\":\"2015-11-11\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C3",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "json_pointer": "/organism",
  "excerpt": "{\"lineage\":[\"Eukaryota\",\"Fungi\",\"Dikarya\",\"Ascomycota\",\"Pezizomycotina\",\"Eurotiomycetes\",\"Eurotiomycetidae\",\"Eurotiales\",\"Aspergillaceae\",\"Aspergillus\",\"Circumdati\"],\"scientificName\":\"Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 / M93)\",\"taxonId\":1509407}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C4",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "json_pointer": "/proteinDescription",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Restricticin biosynthesis cluster protein 7\"}}],\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000305\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"1.-.-.-\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Trans-enoyl reductase rstn7\"}}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C5",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "json_pointer": "/comments/1",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Antifungal biosynthesis\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json)

```json
{
  "evidence_id": "C6",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEX1.json",
  "source_sha256": "93c2ef537b4216da1fc60d3e1a5b3b72e3ab1e402adbf6bf0765a355bb253bef",
  "retrieved_utc": "2026-11-02T04:24:12.830871+00:00",
  "json_pointer": "/references/1",
  "excerpt": "{\"citation\":{\"authors\":[\"Liu N.\",\"Abramyan E.D.\",\"Cheng W.\",\"Perlatti B.\",\"Harvey C.J.B.\",\"Bills G.F.\",\"Tang Y.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"33857369\"},{\"database\":\"DOI\",\"id\":\"10.1021/jacs.1c01516\"}],\"citationType\":\"journal article\",\"firstPage\":\"6043\",\"id\":\"33857369\",\"journal\":\"J. Am. Chem. Soc.\",\"lastPage\":\"6047\",\"publicationDate\":\"2021\",\"title\":\"Targeted genome mining reveals the biosynthetic gene clusters of natural product CYP51 inhibitors.\",\"volume\":\"143\"},\"referenceNumber\":2,\"referencePositions\":[\"FUNCTION\",\"PATHWAY\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28)

```json
{
  "evidence_id": "H1",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28",
  "source_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "retrieved_utc": "2026-11-02T04:24:15.236581+00:00",
  "source_locator": "lines 1-15",
  "excerpt": "ID   RSTN7_ASPN3             Reviewed;         353 AA.\nAC   A0A0L1JEX1;\nDT   05-FEB-2025, integrated into UniProtKB/Swiss-Prot.\nDT   11-NOV-2015, sequence version 1.\nDT   28-JAN-2026, entry version 28.\nDE   RecName: Full=Trans-enoyl reductase rstn7 {ECO:0000303|PubMed:33857369};\nDE            EC=1.-.-.- {ECO:0000305|PubMed:33857369};\nDE   AltName: Full=Restricticin biosynthesis cluster protein 7 {ECO:0000303|PubMed:33857369};\nGN   Name=rstn7 {ECO:0000303|PubMed:33857369}; ORFNames=ANOM_001446;\nOS   Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 /\nOS   M93).\nOC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;\nOC   Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;\nOC   Aspergillus subgen. Circumdati.\nOX   NCBI_TaxID=1509407;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 28,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28)

```json
{
  "evidence_id": "H2",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28",
  "source_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "retrieved_utc": "2026-11-02T04:24:15.236581+00:00",
  "source_locator": "lines 24-31",
  "excerpt": "RN   [2]\nRP   FUNCTION, AND PATHWAY.\nRX   PubMed=33857369; DOI=10.1021/jacs.1c01516;\nRA   Liu N., Abramyan E.D., Cheng W., Perlatti B., Harvey C.J.B., Bills G.F.,\nRA   Tang Y.;\nRT   \"Targeted genome mining reveals the biosynthetic gene clusters of natural\nRT   product CYP51 inhibitors.\";\nRL   J. Am. Chem. Soc. 143:6043-6047(2021).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 28,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28)

```json
{
  "evidence_id": "H3",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEX1?format=txt&versions=28",
  "source_sha256": "b0c5088300010a6f92ba849941ad2568759c78d66be84ee67a93fca4e39f4e91",
  "retrieved_utc": "2026-11-02T04:24:15.236581+00:00",
  "source_locator": "lines 47-47",
  "excerpt": "CC   -!- PATHWAY: Antifungal biosynthesis. {ECO:0000269|PubMed:33857369}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 28,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 197. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
